Company news

XtalPi Holdings Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Voluntary announcement increase in shareholding in the company by the chairman of the board

October 7, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 6, 2026

Next Day Disclosure Return

October 5, 2026

XtalPi Advances Hair Loss Drug Program into IND-Enabling Studies

October 2, 2026

XtalPi and Fangda Carbon Deploy Predictive AI to Optimize Cost and Material Efficiency in Graphite Electrode Manufacturing

October 2, 2026

Next Day Disclosure Return

October 2, 2026

XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain

September 24, 2026

Grant of share options and restricted share units

September 23, 2026

XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program

September 22, 2026

Voluntary announcement plan to increase shareholding in the company by the chairman of the board

September 20, 2026

Voluntary announcement strategic drug discovery collaboration between xtalpi subsidiary LCC technologies and stanford university

September 17, 2026

XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026

August 12, 2026

XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target

June 10, 2026

XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies

May 29, 2026

XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway

May 3, 2026

XtalPi Holdings Announces Full Year 2025 Annual Results

March 25, 2026

XtalPi Holdings Limited to Announce 2025 Annual Results on March 25, 2026

March 13, 2026

XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117

March 2, 2026

Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF

February 9, 2026

XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision

January 29, 2026

XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development

November 5, 2025

XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals

September 9, 2025

XtalPi Holdings Announces 2025 Interim Results

August 27, 2025

XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies

August 19, 2025

XtalPi Holdings Limited to Announce 2025 Interim Results on August 27, 2025

August 18, 2025

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

August 6, 2025

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

June 29, 2025

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

June 22, 2025

XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration

June 13, 2025

XtalPi and Kula Bio Forge Multi-Million USD Collaborative R&D Agreement to Advance AI-Driven Microbial Fertilizers in China and the Middle East

March 28, 2025

Decks

The 5 newest of 8 decks. Every deck is listed under its year.